115 related articles for article (PubMed ID: 31796073)
1. NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2
Jacobs SA; Robidoux A; Abraham J; Pérez-Garcia JM; La Verde N; Orcutt JM; Cazzaniga ME; Piette F; Antolín S; Aguirre E; Cortes J; Llombart-Cussac A; Di Cosimo S; Kim RS; Feng H; Lipchik C; Lucas PC; Srinivasan A; Wang Y; Song N; Gavin PG; Balousek AD; Paik S; Allegra CJ; Wolmark N; Pogue-Geile KL
Breast Cancer Res; 2019 Dec; 21(1):133. PubMed ID: 31796073
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Albain KS; Yau C; Petricoin EF; Wolf DM; Lang JE; Chien AJ; Haddad T; Forero-Torres A; Wallace AM; Kaplan H; Pusztai L; Euhus D; Nanda R; Elias AD; Clark AS; Godellas C; Boughey JC; Isaacs C; Tripathy D; Lu J; Yung RL; Gallagher RI; Wulfkuhle JD; Brown-Swigart L; Krings G; Chen YY; Potter DA; Stringer-Reasor E; Blair S; Asare SM; Wilson A; Hirst GL; Singhrao R; Buxton M; Clennell JL; Sanil A; Berry S; Asare AL; Matthews JB; DeMichele AM; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Symmans WF; Van't Veer LJ; Yee D; Berry DA; Esserman LJ
Clin Cancer Res; 2024 Feb; 30(4):729-740. PubMed ID: 38109213
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
Wulfkuhle JD; Yau C; Wolf DM; Vis DJ; Gallagher RI; Brown-Swigart L; Hirst G; Voest EE; DeMichele A; Hylton N; Symmans F; Yee D; Esserman L; Berry D; Liu M; Park JW; Wessels LFA; Van't Veer L; Petricoin EF
JCO Precis Oncol; 2018; 2():. PubMed ID: 32914002
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
Lang JE; Forero-Torres A; Yee D; Yau C; Wolf D; Park J; Parker BA; Chien AJ; Wallace AM; Murthy R; Albain KS; Ellis ED; Beckwith H; Haley BB; Elias AD; Boughey JC; Yung RL; Isaacs C; Clark AS; Han HS; Nanda R; Khan QJ; Edmiston KK; Stringer-Reasor E; Price E; Joe B; Liu MC; Brown-Swigart L; Petricoin EF; Wulfkuhle JD; Buxton M; Clennell JL; Sanil A; Berry S; Asare SM; Wilson A; Hirst GL; Singhrao R; Asare AL; Matthews JB; Melisko M; Perlmutter J; Rugo HS; Symmans WF; van 't Veer LJ; Hylton NM; DeMichele AM; Berry DA; Esserman LJ
NPJ Breast Cancer; 2022 Dec; 8(1):128. PubMed ID: 36456573
[TBL] [Abstract][Full Text] [Related]
5. Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
Arshad M; Azad A; Chan PYK; Vigneswara V; Feldinger K; Nafi SNM; Laporte-Maguire E; De Santo C; Zuo J; Shaaban AM; Kong A
Br J Cancer; 2024 Apr; ():. PubMed ID: 38600326
[TBL] [Abstract][Full Text] [Related]
6. Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA; Wang Y; Abraham J; Feng H; Montero AJ; Lipchik C; Finnigan M; Jankowitz RC; Salkeni MA; Maley SK; Puhalla SL; Piette F; Quinn K; Chang K; Nagy RJ; Allegra CJ; Vehec K; Wolmark N; Lucas PC; Srinivasan A; Pogue-Geile KL
Breast Cancer Res; 2024 May; 26(1):83. PubMed ID: 38790033
[No Abstract] [Full Text] [Related]
7. Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot Study.
Wong CW; Yost SE; Lee JS; Gillece JD; Folkerts M; Reining L; Highlander SK; Eftekhari Z; Mortimer J; Yuan Y
Front Oncol; 2021; 11():604584. PubMed ID: 33796451
[TBL] [Abstract][Full Text] [Related]
8. NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab.
Ganz PA; Cecchini RS; Fehrenbacher L; Geyer CE; Rastogi P; Crown JP; Thirlwell MP; Ellison DM; Boileau JF; Flynn PJ; Jeong JH; Mamounas EP; Wolmark N
NPJ Breast Cancer; 2021 May; 7(1):55. PubMed ID: 34016989
[TBL] [Abstract][Full Text] [Related]
9. Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Jacobs SA; Robidoux A; Abraham J; Pérez-Garcia JM; La Verde N; Orcutt JM; Cazzaniga ME; Piette F; Antolín S; Aguirre E; Cortes J; Llombart-Cussac A; Di Cosimo S; Kim RS; Feng H; Lipchik C; Lucas PC; Srinivasan A; Wang Y; Song N; Gavin PG; Balousek AD; Paik S; Allegra CJ; Wolmark N; Pogue-Geile KL
Breast Cancer Res; 2020 Jan; 22(1):9. PubMed ID: 31969184
[TBL] [Abstract][Full Text] [Related]
10. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
[TBL] [Abstract][Full Text] [Related]
11. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Saura C; Oliveira M; Feng YH; Dai MS; Chen SW; Hurvitz SA; Kim SB; Moy B; Delaloge S; Gradishar W; Masuda N; Palacova M; Trudeau ME; Mattson J; Yap YS; Hou MF; De Laurentiis M; Yeh YM; Chang HT; Yau T; Wildiers H; Haley B; Fagnani D; Lu YS; Crown J; Lin J; Takahashi M; Takano T; Yamaguchi M; Fujii T; Yao B; Bebchuk J; Keyvanjah K; Bryce R; Brufsky A;
J Clin Oncol; 2020 Sep; 38(27):3138-3149. PubMed ID: 32678716
[TBL] [Abstract][Full Text] [Related]
12. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Fernandez-Martinez A; Krop IE; Hillman DW; Polley MY; Parker JS; Huebner L; Hoadley KA; Shepherd J; Tolaney S; Henry NL; Dang C; Harris L; Berry D; Hahn O; Hudis C; Winer E; Partridge A; Perou CM; Carey LA
J Clin Oncol; 2020 Dec; 38(35):4184-4193. PubMed ID: 33095682
[TBL] [Abstract][Full Text] [Related]
13. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
15. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Chan A; Moy B; Mansi J; Ejlertsen B; Holmes FA; Chia S; Iwata H; Gnant M; Loibl S; Barrios CH; Somali I; Smichkoska S; Martinez N; Alonso MG; Link JS; Mayer IA; Cold S; Murillo SM; Senecal F; Inoue K; Ruiz-Borrego M; Hui R; Denduluri N; Patt D; Rugo HS; Johnston SRD; Bryce R; Zhang B; Xu F; Wong A; Martin M;
Clin Breast Cancer; 2021 Feb; 21(1):80-91.e7. PubMed ID: 33183970
[TBL] [Abstract][Full Text] [Related]
16. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
Xu B; Yan M; Ma F; Hu X; Feng J; Ouyang Q; Tong Z; Li H; Zhang Q; Sun T; Wang X; Yin Y; Cheng Y; Li W; Gu Y; Chen Q; Liu J; Cheng J; Geng C; Qin S; Wang S; Lu J; Shen K; Liu Q; Wang X; Wang H; Luo T; Yang J; Wu Y; Yu Z; Zhu X; Chen C; Zou J;
Lancet Oncol; 2021 Mar; 22(3):351-360. PubMed ID: 33581774
[TBL] [Abstract][Full Text] [Related]
17. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
18. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
; Yee D; DeMichele AM; Yau C; Isaacs C; Symmans WF; Albain KS; Chen YY; Krings G; Wei S; Harada S; Datnow B; Fadare O; Klein M; Pambuccian S; Chen B; Adamson K; Sams S; Mhawech-Fauceglia P; Magliocco A; Feldman M; Rendi M; Sattar H; Zeck J; Ocal IT; Tawfik O; LeBeau LG; Sahoo S; Vinh T; Chien AJ; Forero-Torres A; Stringer-Reasor E; Wallace AM; Pusztai L; Boughey JC; Ellis ED; Elias AD; Lu J; Lang JE; Han HS; Clark AS; Nanda R; Northfelt DW; Khan QJ; Viscusi RK; Euhus DM; Edmiston KK; Chui SY; Kemmer K; Park JW; Liu MC; Olopade O; Leyland-Jones B; Tripathy D; Moulder SL; Rugo HS; Schwab R; Lo S; Helsten T; Beckwith H; Haugen P; Hylton NM; Van't Veer LJ; Perlmutter J; Melisko ME; Wilson A; Peterson G; Asare AL; Buxton MB; Paoloni M; Clennell JL; Hirst GL; Singhrao R; Steeg K; Matthews JB; Asare SM; Sanil A; Berry SM; Esserman LJ; Berry DA
JAMA Oncol; 2020 Sep; 6(9):1355-1362. PubMed ID: 32701140
[TBL] [Abstract][Full Text] [Related]
19. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response.
Swain SM; Tang G; Brauer HA; Goerlitz DS; Lucas PC; Robidoux A; Harris BT; Bandos H; Ren Y; Geyer CE; Rastogi P; Mamounas EP; Wolmark N
Clin Cancer Res; 2020 Aug; 26(16):4233-4241. PubMed ID: 32371537
[TBL] [Abstract][Full Text] [Related]
20. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis.
Nasrazadani A; Brufsky A
Future Oncol; 2020 Mar; 16(7):247-254. PubMed ID: 32057254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]